Literature DB >> 6457001

Tumor biopsy cells participating in systems in which cytotoxicity of lymphocytes is generated. Autologous and allogeneic studies.

F Vánky, S Argov, E Klein.   

Abstract

Freshly separated tumor cells from sarcomas and carcinomas were used in various roles in lymphocyte-target cell interaction assays. They were poorer allogeneic stimulators than lymphocytes. They were however good allotargets for the cytotoxicity generated in mixed lymphocyte cultures. They were also killed as third party targets by lymphocytes activated in MLC. In a proportion of experiments, lymphocytes activated in MLC killed autologous tumor cells. Autotumor killer effect was generated in the majority of mixed cultures containing lymphocytes and tumor biopsy cells from the same individual. Generation of cytotoxicity against K562 was a good measure of lymphocyte activation and could be used as a sensitive indicator for the occurrence of the recognition step in the mixed cultures. We propose that for the search of lymphocytes with specific receptors, activation is a more reliable parameter than specific cytotoxicity since the latter function is also influenced by the sensitivity of the target. The results confirmed that patients with carcinomas and sarcomas possess autotumor-reactive lymphocytes. These can be activated for cytotoxicity by in vitro confrontation with the tumor cells and occasionally through stimulation which is unrelated to the tumor cells.

Entities:  

Mesh:

Year:  1981        PMID: 6457001     DOI: 10.1002/ijc.2910270304

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

Review 1.  Lymphocyte-mediated lysis of tumor cells in vitro. Antigen-restricted clonal and unrestricted polyclonal effects.

Authors:  E Klein
Journal:  Springer Semin Immunopathol       Date:  1982

2.  Auto-tumor lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity.

Authors:  F Vánky; E Klein
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells.

Authors:  F Vánky; P Wang; E Klein
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Inhibition of the generation of cytotoxic lymphocytes by potassium ion channel blockers.

Authors:  B Sharma
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

5.  In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission.

Authors:  R Somasundaram; S G Rao; S H Advani; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  The role of allogeneic cells in the stimulation of cell-mediated cytotoxicity to leukaemia cells. A family study.

Authors:  G M Taylor; B A Bradley
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Human T-cell cultures with selective autotumor reactivity.

Authors:  F Vánky; E Klein
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

8.  Effect of simple sugars on natural killing: evidence against the involvement of a lectin like mechanism in target recognition.

Authors:  B M Vose; M Harding; W White; M Moore; J Gallagher
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

9.  DR antigens expressed on tumor cells do not contribute to the blastogenetic response of autologous T cells.

Authors:  F Vánky; E Klein; J Willems
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture--no correlation with the postsurgical clinical course.

Authors:  F Vánky; E Klein; J Willems; K Böök; T Ivert; A Péterffy; U Nilsonne; A Kreicbergs
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.